New Advances of Somatostatin Receptor-targeted Radionuclide Therapy for Neuroendocrine Tumors

Radiolabeled Somatostatin Analogues in clinical applications include ()~(111)In-Pentetreotide,()~(90)Y-DOTATOC,()~(177)Lu-octreotate and()~(90)Y-DOTALAN,After these radiopharmacies bind with SSTR2s which are overexpressed on the cell membrane,they can produce both chemotherapy and radiotherapy effects on neuroendocrine tumors.The researches indicat that SRTRT(Somatostatin Receptor-targeted Radionuclide Therapy) is a promising treatment for neuroendocrine tumors because of its better curative effect,less side effect and less toxicity.The curative effect of()~(177)Lu-octreotate and ()~(90)Y-DOTALAN is better than that of()~(111)In-pentetreotide and()~(90)Y-DOTATOC,the rate of complete remission and partial remission is above 40% and the rate of stable disease is 45%.